RFCA
LAB icon

R&F Capital Advisors’s Standard BioTools LAB Stock Holding History

R&F Capital Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$83K Buy
+14,500
New +$91.9K 0.02% 627

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

R&F Capital Advisors's LAB Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Standard BioTools (LAB) in Q1 2017: 14,500 shares worth $83K. The stake represents 0.02% of the portfolio and ranks #627 among its holdings.

80 funds tracked by Wall St. Rank hold LAB as of Q1 2017.

  • R&F Capital Advisors held 14,500 shares of Standard BioTools worth $83K as of Q1 2017.
  • Standard BioTools was a new R&F Capital Advisors position in Q1 2017.
  • Standard BioTools made up 0.02% of R&F Capital Advisors's portfolio in Q1 2017, its #627 holding.
  • 80 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.